What went well
- Published ARD-101 clinical and preclinical data in the peer-reviewed journal Molecular Metabolism, showing a statistically significant reduction in self-reported hunger (Control of Eating Questionnaire) versus placebo at Day 28 and engagement of gut-brain hunger pathways, including increased post-dose PYY and GLP-1.
- Management reaffirmed confidence in ARD-101, citing prior positive clinical data, an encouraging historical safety profile, and a newly characterized exposure-response relationship indicating that lower doses (e.g., 200 mg twice daily) yield plasma concentrations well below the threshold at which the QRS effect was observed.
- Ended 2025 with $110.0 million in cash, cash equivalents and short-term investments (up from $73.7 million a year earlier following the IPO), sufficient to fund operations into the second quarter of 2027.
What went wrong
- In February 2026 Aardvark voluntarily paused enrollment and dosing in the Phase 3 HERO and open-label extension trials of ARD-101 for PWS after unexpected reversible cardiac observations (QRS prolongation) in a separate healthy-volunteer cardiac-safety study, where participants were dosed at twice the HERO target dose without dose escalation.
- The company also voluntarily paused its entire ARD-201 obesity program, including the POWER and STRENGTH trials, pending next steps on ARD-101, and deferred further guidance on all programs to the second quarter of 2026.
- Losses accelerated sharply: full-year net loss rose to $57.6 million from $20.6 million (fourth-quarter net loss of $17.6 million vs. $8.8 million), with full-year R&D up to $48.9 million from $17.4 million and full-year G&A up to $13.8 million from $5.3 million.
Guidance Changes
| Metric | Period | Current guidance |
|---|---|---|
| Cash runway | As of December 31, 2025 | $110.0M in cash, equivalents and short-term investments; funds projected operations into Q2 2027 |
| ARD-101 (PWS) program next steps | Q2 2026 | Further guidance expected in the second quarter of 2026 following FDA engagement |
| ARD-201 (obesity) program next steps | Q2 2026 | Program voluntarily paused; further guidance expected in the second quarter of 2026 |
| ARD-101 HERO Phase 3 topline | Under review | Previously guided to Q3 2026; timing under review following the voluntary pause |
Performance Breakdown
| Metric | YoY | Note |
|---|---|---|
| Full-year R&D expense | $48.9M (vs $17.4M) | $31.6M increase, including $23.4M more external spend on ARD-101 development and $7.7M more personnel costs. |
| Full-year G&A expense | $13.8M (vs $5.3M) | $8.5M increase from higher personnel, professional-services, facilities and insurance costs as a public company. |
| Full-year net loss | $57.6M (vs $20.6M) | Driven by higher R&D and G&A spend across the year. |
| Fourth-quarter net loss | $17.6M (vs $8.8M) | Higher clinical development and G&A spend in the quarter. |
| Cash, equivalents & short-term investments | $110.0M | Down from $126.4M at Q3 2025; funds operations into Q2 2027. |
| Fourth-quarter diluted net loss per share | $(0.81) | Q4 loss per share; full-year loss per share was $(2.93). |
Earnings Call Themes & Trends
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| ARD-101 in PWS (HERO) | FDA-aligned and enrolling with OLE | Voluntarily paused (February 2026) after a reversible cardiac QRS signal; FDA engagement underway | Down |
| ARD-201 obesity program | Two Phase 2 trials initiating | Voluntarily paused pending ARD-101 next steps | Down |
| ARD-101 evidence base | ObesityWeek 2025 data | Peer-reviewed Molecular Metabolism publication supporting hunger-signal effects | Up |
| Cash runway | $126.4M into 2027 | $110.0M into Q2 2027 | Steady |
More on Aardvark Therapeutics, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.